Asymmetric Dialysis: Truly Unified and Simultaneous Single‐Pass Concentration and Buffer Exchange
Biotechnology and Bioengineering · 2026
DOI: 10.1002/bit.70218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Bioengineering, 2026. Verfasst von Ujwal Patil und 3 weiteren Autor:innen. Beteiligte Einrichtung: Bioprocess Technologies and Engineering, Biopharmaceutical Development, AstraZeneca, Gaithersburg, Maryland, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Biopharmaceutical manufacturing has been using ultrafiltration (UF) and diafiltration (DF) for buffer exchange, desalting, and formulation of biologics. The legacy UF/DF is commonly a two‐step batch process that is challenging to integrate into end‐to‐end continuous biomanufacturing. Here, we introduce asymmetric dialysis, a novel one‐step continuous process that combines UF and DF. It works by utilizing asymmetric flow between the inlet and outlet of the retentate and complementary flow of the dialysate solution, achieving product concentration, buffer exchange, and salt removal using a commercially available hollow fiber device. Asymmetric dialysis can achieve product concentrations of 105 (3.8×), 200 (10×), and 64 g/L (9.4×) starting from feed concentrations of 30, 20, and 7 g/L, respectively, with modest pressures of 6–7 psi. The interplay between feed and exchange buffer flow rates was exploited to make the process sustainable by reducing buffer consumption by 75% (25 L/kg mAb) compared to conventional batch UF/DF (100 L/kg, mAb). We successfully processed 7 kg of mAb at 20 g/L feed using 5‐day asymmetric dialysis with a daily productivity of 0.8 kg/m 2 /day to product concentration of 200 g/L. These results demonstrate the potential of asymmetric dialysis, a simple, sustainable, and low‐cost bioprocessing technology for continuous bioprocessing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioprocess Technologies and Engineering, Biopharmaceutical Development, AstraZeneca, Gaithersburg, Maryland, USA.
ORCID-Profile: Ujwal Patil, Irina Ramos
Förderung
- AstraZeneca
Zitieren
APA
Patil, U., Chen, M., Ramos, I., & Coffman, J. (2026). Asymmetric Dialysis: Truly Unified and Simultaneous Single‐Pass Concentration and Buffer Exchange. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.70218
Vancouver
Patil U, Chen M, Ramos I, Coffman J. Asymmetric Dialysis: Truly Unified and Simultaneous Single‐Pass Concentration and Buffer Exchange. Biotechnology and Bioengineering. 2026. doi:10.1002/bit.70218
BibTeX
@article{Patil2026,
author = {Patil, Ujwal and Chen, Michelle and Ramos, Irina and Coffman, Jon},
title = {Asymmetric Dialysis: Truly Unified and Simultaneous Single‐Pass Concentration and Buffer Exchange},
journal = {Biotechnology and Bioengineering},
year = {2026},
doi = {10.1002/bit.70218}
}
EUVIMED